Background Cognitive impairment is a common nonmotor manifestation of Parkinson's
disease, with deficits ranging from mild cognitive difficulties in 1 or more of the cognitive …

Safinamide (Xadago®) is an orally active, selective, reversible monoamine oxidase-B
inhibitor with both dopaminergic and non-dopaminergic (glutamatergic) properties. In the …

Background The number of patients with neurological diseases is currently increasing
annually, which presents tremendous challenges for both patients and doctors. With the …

Background The main objective of this paper is to develop and test the ability of the Leap
Motion controller (LMC) to assess the motor dysfunction in patients with Parkinson disease …

Abstract People with Parkinson's Disease (PD) might struggle with sadness, restlessness, or
difficulty speaking, chewing, or swallowing. A diagnosis can be challenging because there is …

Parkinson's disease (PD) is characterised by degeneration of dopaminergic neurons of the
nigrostriatal pathway, which leads to the cardinal motor symptoms of the disease-tremor …

Parkinson's disease (PD) is the second most prevalent neurodegenerative disease
worldwide, affecting more than four million people. Typically, it affects individuals above 45 …

Parkinson's disease is characterized by the loss of dopaminergic neurons in substantia
nigra pars compacta (SNpc) and the resultant loss of dopamine in the striatum. Various …

Objective This study aimed to explore the association between malnutrition, clinical
parameters, and health-related quality of life in elderly hospitalized patients with Parkinson's …

Introduction Treatment adjustments in Parkinson's disease (PD) are in part dependent on
motor assessments. The aim of this study was to evaluate the cost-effectiveness of home …